Video
Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma
Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.
Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.
In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab.
In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.
<<<
.jpg?fit=crop&auto=format)
